


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (1):



as a single tautomer, a mixture of tautomers, a single stereoisomer, a mixture of stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt or solvate thereof; wherein:

$R^1$ ,  $R^2$  and  $R^3$  at each occurrence is independently selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol, thioureido, and ureido; and

$R^4$  is selected from hydrogen, heteroalkyl, heteroaryl, and hydrocarbyl.

2. (Previously Presented) A composition according to Claim 1 wherein heteroalkyl is selected from aminohydrocarboyl, amido, carboxylic acid, cyano, dihydrocarbylamido, dihydrocarbylamino, di(hydrocarbyl)phosphido, formyl,

hydrocarbonyl, hydrocarboxyloxy, hydrocarbylamino, hydrocarbyloxy, hydrocarbyloxycarbonyl, hydrocarbylsiloxy, hydrocarbylsilylamino, hydrocarbylsulfido, hydrocarbylthio, hydrocarbylamido, isothiocyanate, *N*-heterocycle, perfluorohydrocarbonyl, thiocyanate, and hydrocarbyl substituted with one or more groups selected from alkylamino, amino, aminosulfinyl, aminosulfonyl, azido, dialkylamino, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol, thioureido, and ureido.

3. (Previously Presented) The composition of Claim 1 where hydrocarbyl is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, and aryl, where

alkyl, alkenyl and alkynyl are each optionally substituted with one or more  $\text{Hy}^1$  groups selected from cycloalkyl, cycloalkylene and aryl, where each  $\text{Hy}^1$  group is optionally substituted with one or more  $\text{Hy}^2$  groups selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, and aryl; and

cycloalkyl, cycloalkylene and aryl are each optionally substituted with one or more  $\text{Hy}^2$  groups selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene and aryl;

provided that when  $\text{Hy}^2$  is selected from alkyl, alkenyl or alkynyl, then  $\text{Hy}^2$  may be substituted with one or more  $\text{Hy}^3$  groups selected from cycloalkyl, cycloalkylene and aryl, where each  $\text{Hy}^3$  group is optionally substituted with one or more  $\text{Hy}^4$  groups selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, and aryl, and when  $\text{Hy}^2$  is selected from cycloalkyl, cycloalkylene and aryl then  $\text{Hy}^2$  is optionally substituted with one or more  $\text{Hy}^4$  groups; and

further provided that aryl includes an aryl ring fused to a non-aromatic hydrocarbocyclic ring.

4. (Previously Presented) The composition of Claim 1 wherein R<sup>1</sup> at each occurrence is hydrogen.

5. (Previously Presented ) The composition of Claim 1 wherein R<sup>4</sup> is hydrogen.

6. (Previously Presented) The composition of Claim 1 wherein R<sup>4</sup> is C<sub>1</sub>-C<sub>8</sub> hydrocarbonyl.

7. (Previously Presented) The composition of Claim 1 wherein R<sup>2</sup> is hydrogen.

8. (Previously Presented) The composition of Claim 1 wherein R<sup>2</sup> is selected from lower alkyl and lower haloalkyl.

9. (Currently Amended) The composition of ~~any one of~~ Claim 1 wherein R<sup>2</sup> is amino.

10. (Currently Amended) The composition of ~~any one of~~ Claim 1 wherein R<sup>2</sup> is heterocycle.

11. (Previously Presented) The composition of Claim 1 wherein R<sup>2</sup> is N-heterocycle.

12. (Previously Presented) The composition of Claim 1 wherein  $R^2$  is hydrocarbyl.

13. (Previously Presented) The composition of Claim 1 wherein  $R^3$  is hydrogen.

14. (Previously Presented) The composition of Claim 1 wherein  $R^3$  is selected from phenyl and substituted phenyl.


15. (Original) The composition of Claim 14 wherein  $R^3$  is phenyl substituted with one or more substituents selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol, thioureido, and ureido.

16. (Original) The composition of Claim 14 wherein  $R^3$  is phenyl substituted with one or more substituents selected from hydroxyl, lower alkoxy, lower alkyl,

17. (Previously Presented) The composition of Claim 1 wherein  $R^3$  is heteroalkyl.

18. (Previously Presented) The composition of Claim 1 wherein  $R^3$  is selected from amino, hydrocarbylamino and dihydrocarbylamino.

19. (Original) The composition of Claim 18 wherein  $R^3$  is hydrocarbylamino where hydrocarbyl is aralkyl.
20. (Original) The composition of Claim 18 wherein  $R^3$  is hydrocarbylamino where hydrocarbyl is alkyl.
21. (Original) The composition of Claim 18 wherein  $R^3$  is amino.
22. (Previously Presented) The composition of Claim 1 wherein  $R^3$  is hydrocarbyl.
23. (Previously Presented) A compound of formula (1):




as a single tautomer, a mixture of tautomers, a single stereoisomer, a mixture of stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt or solvate thereof; wherein:

$R^1$  and  $R^2$  at each occurrence is independently selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol, thioureido, and ureido;

$R^3$  is selected from heterocycle, hydrogen, halogen-substituted hydrocarbyl and hydrocarbyl; and

$R^4$  is selected from hydrogen, heteroalkyl, heteroaryl, and hydrocarbyl.

24. (Original) A compound of formula (1):



as a single tautomer, a mixture of tautomers, a single stereoisomer, a mixture of stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt or solvate thereof; wherein:

$R^1$  each occurrence is independently selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol, thioureido, and ureido;


$R^2$  is amino;

$R^3$  is selected from hydrocarbyl, -O-hydrocarbyl and -S-hydrocarbyl; and

$R^4$  is selected from hydrogen, heteroalkyl, heteroaryl, and hydrocarbyl.

25-26. (Canceled)

27. (Original) A compound of formula (1):




as a single tautomer, a mixture of tautomers, a single stereoisomer, a mixture of stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt or solvate thereof; wherein:

$R^1$ ,  $R^2$  and  $R^3$  at each occurrence is independently selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol, thioureido, and ureido, with the proviso that  $R^1$  is not hydrogen in at least one occurrence of  $R^1$ ; and

$R^4$  is selected from hydrogen, heteroalkyl, heteroaryl, and hydrocarbyl.

28. (Canceled)

29. (Original) A compound of formula (2):



as a single tautomer, a mixture of tautomers, a single stereoisomer, a mixture of stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt or solvate thereof; wherein:

$R^1$  at each occurrence is independently selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol, thioureido, and ureido;

$R^4$  is selected from hydrogen, heteroalkyl, heteroaryl, and hydrocarbyl;  
and

$R^5$ ,  $R^6$ ,  $R^7$  and  $R^8$  at each occurrence is independently selected from heteroalkyl, heteroaryl, hydrocarbyl and hydrogen, with the proviso that  $R^7$  and  $R^8$  may join together to form a heterocyclic ring including the nitrogen to which they are both bonded.

30. (Previously Presented) A method of treating a hyperproliferative disorder, the method comprising: contacting a patient suffering from said hyperproliferative disorder with an effective dose of a composition according to Claim 1 or of a compound according to Claim 23, Claim 24, Claim 27 or Claim 29.



31. (Original) The method of Claim 30, wherein said hyperproliferative disorder comprises the growth of tumor cells, neointimal hyperplasia or lymphoproliferative disorders.

32-33. (Canceled)

34. (Previously Presented) The method according to Claim 30, wherein said hyperproliferative disorder comprises angiogenesis or neovascularization.

35. (Original) The method according to Claim 34, wherein said neovascularization is ocular neovascularization.

36. (Original) The method according to Claim 35, wherein said ocular neovascularization is neovascularization of the cornea, iris, retina or choroid.

37. (Previously Presented) The method according to Claim 35, wherein said ocular neovascularization is associated with age related macular degeneration or with age related diabetic retinopathy.

38. (Canceled)

39. (Original) The method according to Claim 35, further comprising the step of administering a photosensitive agent.

40. (Original) The method according to Claim 39, wherein said photosensitive agent is verteporfin.

41. (Previously Presented) A method of inhibiting cell migration or invasion, the method comprising: contacting a patient suffering from a disorder resulting from said cell migration or invasion with an effective dose of a composition according to Claim 1 or of a compound according to Claim 23, Claim 24, Claim 27 or Claim 29.

42. (Original) The method according to Claim 41, wherein said cells are cancer cells.

43. (Original) The method according to Claim 41, wherein said cells are neutrophils.

44. (Original) The method according to Claim 41, wherein said cells are macrophages.

45. (Previously Presented) A method of inhibiting inflammation, the method comprising: contacting a patient suffering from said inflammation with an effective dose of a composition according to Claim 1 or of a compound according to Claim 23, Claim 24, Claim 27 or Claim 29.

46. (Original) The method according to Claim 45, wherein said inflammation comprises activation of macrophages.

47. (Original) The method according to Claim 46, wherein said inflammation is selected from the group consisting of rheumatoid arthritis, contact dermatitis, allergic dermatitis, and psoriasis.

48. (Original) The method according to Claim 46, wherein said inflammation is associated with asthma.

49. (Previously Presented) A method of treating renal disease, the method comprising: contacting a patient suffering from said renal disease with an effective dose of a composition according to Claim 1 or of a compound according to Claim 23, Claim 24, Claim 27 or Claim 29.

50. (Original) The method according to Claim 49, wherein said disease is caused by hypertension.

51. (Original) The method according to Claim 49, wherein said disease is not caused by hypertension.

52. (Original) The method according to Claim 49, further comprising the step of administering an ACE inhibitor.

53-76. (Canceled)

77. (New) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound selected from the group consisting of:

(4-Benzothiazol-2-yl-1*H*-pyrazol-3-yl)-[2-(1*H*-imidazol-4-yl)-ethyl]-amine;

(4-Benzothiazol-2-yl-2*H*-pyrazol-3-yl)-methyl-amine;

[2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazol-6-yl]-methanol;

[2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-5-yl]-methanol;

[2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-6-yl]-methanol;

2-(1*H*-Pyrazol-4-yl)-benzothiazole;  
2-(1*H*-Pyrazol-4-yl)-benzothiazole-6-sulfonic acid amide;  
2-(3-Amino-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-4,5,6-trifluoro-benzothiazole-7-sulfonic acid  
amide;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazole-6-carboxylic acid methyl  
ester;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid  
methanamide;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-carboxylic acid;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-carboxylic acid methyl ester;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid methanamide;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (2,6-dimethyl-  
pyrimidin-4-yl)-amide;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-benzothiazole-7-carboxylic acid methyl ester;  
2-(3-Methyl-1*H*-pyrazol-4-yl)-benzothiazole;  
2-(4-Benzothiazol-2-yl-1*H*-pyrazol-3-yl)-phenol;  
2-(5-Amino-1*H*-pyrazol-4-yl)-benzothiazol-6-ylamine;  
2-(5-Amino-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid methanamide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-4-fluorobenzothiazole-6-sulfonic acid amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazole-4-sulfonic acid (2-  
hydroxy-ethyl)-amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid (2-  
hydroxy-ethyl)-amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid (pyridin-  
4-ylmethyl)-amide;

2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-5-ol;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-5-sulfonic acid methylamide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-carboxylic acid amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (2-hydroxy-ethyl)-  
amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (2-methoxy-ethyl)-  
amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid 4-fluoro-  
benzylamide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (2-thiophen-2-yl-  
ethyl)-amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid 4-chloro-  
benzylamide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid 4-methoxy-  
benzylamide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid benzylamide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid phenethyl-amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid [2-(4-amino-  
phenyl)-ethyl]-amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (2-morpholin-4-yl-  
ethyl)-amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (2,2,2-trifluoro-  
ethyl)-amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid  
cyclopropylmethyl-amide;

- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid [2-(3*H*-imidazol-4-yl)-ethyl]-amide;
- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid 4-amino-benzylamide;
- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (pyridin-4-ylmethyl)-amide;
- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (2-dimethylamino-ethyl)-amide;
- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (3-dimethylamino-propyl)-amide;
- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (acetic hydrazido) amide;
- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (phenylhydrazino) amide;
- 2-(5-Amino-3-pyridin-4-yl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid amide;
- 2-(5-Amino-4-benzothiazol-2-yl-1*H*-pyrazol-3-ylamino)-ethanol;
- 2-(5-Amino-4-benzothiazol-2-yl-2*H*-pyrazol-3-ylamino)-cyclopentanol;
- 2-{{2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-6-ylmethyl}-amino}-ethanol;
- 3-(5-Amino-4-benzothiazol-2-yl-1*H*-pyrazol-3-yl)-propan-1-ol;
- 3-(5-Amino-4-benzothiazol-2-yl-1*H*-pyrazol-3-ylamino)-propan-1-ol;
- 3-[5-Amino-4-(5-fluoro-6-methoxy-benzothiazol-2-yl)-1*H*-pyrazol-3-ylamino]-propan-1-ol;
- 3-{{2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-6-ylmethyl}-amino}-benzenesulfonamide;
- 4-(4-Benzothiazol-2-yl-1*H*-pyrazol-3-yl)-6-ethyl-benzene-1,3-diol;
- 4-(4-Benzothiazol-2-yl-1*H*-pyrazol-3-yl)-benzene-1,3-diol;
- 4-(4-Benzothiazol-2-yl-1*H*-pyrazol-3-yl)-phenol;

4-(4-fluorobenzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(5-Amino-4-benzothiazol-2-yl-1*H*-pyrazol-3-yl)-butan-1-ol;  
4-(5-Amino-4-benzothiazol-2-yl-1*H*-pyrazol-3-ylamino)-butan-1-ol;  
4-(5-Amino-4-benzothiazol-2-yl-1*H*-pyrazol-3-ylamino)-butyric acid;  
4-(5-Amino-4-benzothiazol-2-yl-2*H*-pyrazol-3-ylamino)-*N*-thiazol-2-yl-  
benzenesulfonamide;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-fluoro-phenyl)-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-phenyl-cyclopropyl)-2*H*-pyrazol-3-  
ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(3-fluoro-phenyl)-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(3-nitro-phenyl)-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(4-fluoro-phenyl)-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(4-methoxy-phenyl)-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(5-nitro-furan-2-yl)-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-furan-2-yl-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-isoxazol-5-yl-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-phenyl-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-piperazin-1-yl-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-pyridin-4-yl-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-thiophen-2-yl-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-*N*<sup>3</sup>-[2-(3*H*-imidazol-4-yl)-ethyl]-1*H*-pyrazole-  
3,5-diamine;  
4-(5-Fluoro-6-methyl-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methyl-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(5-Methoxy-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;

4-(5-Trifluoromethyl-benzothiazol-2-yl)-1*H*-pyrazol-3-ylamine;  
4-(6-Bromo-5-fluoro-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(6-Bromo-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(6-Chlorobenzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(6-Dimethylaminomethyl-5-fluoro-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(6-Dimethylaminomethyl-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(6-Fluoro-benzothiazol-2-yl)-1*H*-pyrazol-3-ylamine;  
4-(6-Fluoro-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(6-Methanesulfonyl-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(6-Methoxy-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(6-Methoxy-benzothiazol-2-yl)-5-piperazin-1-yl-2*H*-pyrazol-3-ylamine;  
4-(6-Nitro-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
4-(7-chloro-4-methoxy-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(7-Chloro-5-fluoro-6-methoxy-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-[(5-Amino-4-benzothiazol-2-yl)-1*H*-pyrazol-3-ylamino)-methyl]-benzenesulfonamide;  
4-[2-(5-Amino-4-benzothiazol-2-yl)-1*H*-pyrazol-3-ylamino)-ethyl]-phenol;  
4-Benzothiazol-2-yl-1*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-5-(3-dimethylamino-propyl)-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-(3-methylamino-propyl)-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-(4-dimethylamino-butyl)-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-(4-methylamino-butyl)-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-(4-nitro-phenyl)-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-cyclopropyl-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-ethyl-1*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-furan-2-yl-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-methyl-1*H*-pyrazol-3-ylamine;



4-Benzothiazol-2-yl-5-methylsulfanyl-1*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-phenyl-1*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-piperazin-1-yl-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-piperidin-4-yl-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-pyridin-3-yl-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-pyridin-4-yl-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-pyrrolidin-1-yl-1*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-thiophen-2-yl-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-(1*H*-imidazol-2-ylmethyl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-(1*H*-imidazol-2-ylmethylene)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-(2-dimethylamino-ethyl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-(2-ethylamino-ethyl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-(2-methoxy-ethyl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-(2-pyrrolidin-1-yl-ethyl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-(3-dimethylamino-propyl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-(3-imidazol-1-yl-propyl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-[2-(1*H*-indol-3-yl)-ethyl]-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-piperidin-4-ylmethyl-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>5</sup>-(2-morpholin-4-yl-ethyl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>5</sup>-ethyl-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>5</sup>-pyridin-3-ylmethyl-1*H*-pyrazole-3,5-diamine;  
5-(2-Chloro-pyridin-3-yl)-4-(5-fluoro-6-methoxy-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
5-(3-Amino-propyl)-4-benzothiazol-2-yl-2*H*-pyrazol-3-ylamine;  
5-(4-Amino-phenyl)-4-benzothiazol-2-yl-2*H*-pyrazol-3-ylamine;  
5-Cyclopropyl-4-(5-fluoro-6-methoxy-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
5-Methyl-4-(4,5,6-trifluoro-benzothiazol-2-yl)-1*H*-pyrazol-3-ylamine;

5-Methyl-4-(5-trifluoromethylbenzothiazol-2-yl)-1*H*-pyrazol-3-ylamine;  
5-Methyl-4-(6-methylaminomethyl-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
5-Methyl-4-(6-morpholin-4-ylmethyl-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
5-Methyl-4-(6-pyrrolidin-1-ylmethyl-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
5-Methyl-4-[6-(4-methyl-piperazin-1-ylmethyl)-benzothiazol-2-yl]-2*H*-pyrazol-3-ylamine;  
5-Methyl-4-[6-(4-methyl-piperazine-1-sulfonyl)-benzothiazol-2-yl]-2*H*-pyrazol-3-ylamine;  
N-[2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-6-yl]-acetamide;  
N-[2-(5-Amino-4-benzothiazol-2-yl-1*H*-pyrazol-3-ylamino)-ethyl]-acetamide;  
N-[4-(5-Amino-4-benzothiazol-2-yl-1*H*-pyrazol-3-yl)-phenyl]-hydroxylamine;  
N-{2-[2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonylamino]-ethyl}-acetamide;  
N-{2-[5-Amino-4-(5-fluoro-6-methoxy-benzothiazol-2-yl)-1*H*-pyrazol-3-ylamino]-ethyl}-acetamide;  
*N*<sup>3</sup>-(2-Amino-ethyl)-4-benzothiazol-2-yl-1*H*-pyrazole-3,5-diamine;  
*N*<sup>3</sup>-(2-Dimethylamino-ethyl)-4-(5-fluoro-6-methoxy-benzothiazol-2-yl)-1*H*-pyrazole-3,5-diamine;  
*N*<sup>3</sup>-(3-Dimethylamino-propyl)-4-(5-fluoro-6-methoxy-benzothiazol-2-yl)-1*H*-pyrazole-3,5-diamine;  
*N*<sup>3</sup>-(4-Amino-phenyl)-4-benzothiazol-2-yl-1*H*-pyrazole-3,5-diamine;  
*N*<sup>3</sup>-[2-(3*H*-Imidazol-4-yl)-ethyl]-4-(6-methoxy-benzothiazol-2-yl)-1*H*-pyrazole-3,5-diamine;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)benzothiazole-5-carboxylic acid ethyl ester;  
4-Benzothiazol-2-yl-*N*<sup>5</sup>-benzyl-1*H*-pyrazole-3,5-diamine; ;  
4-Benzothiazol-2-yl-5-morpholin-4-yl-1*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-(4-methylpiperazin-1-yl)-1*H*-pyrazol-3-ylamine;

4-Benzothiazol-2-yl-*N*<sup>5</sup>-(3,5-dichlorophenyl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>5</sup>-(3-trifluoromethanesulfonyl-phenyl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>5</sup>-quinolin-6-yl-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-quinolin-5-yl-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>5</sup>-pyridin-3-yl-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>5</sup>-pyridin-4-ylmethyl-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-(3-methylbutyl)-1*H*-pyrazole-3,5-diamine;  
2-(3-Phenyl-1*H*-pyrazol-4-yl)benzothiazole;  
2-[3-(4-Methoxyphenyl)-1*H*-pyrazol-4-yl]benzothiazole;  
2-[3-(2-Methoxyphenyl)-1*H*-pyrazol-4-yl]benzothiazole; and  
4-Benzothiazol-2-yl-2-methyl-2*H*-pyrazol-3-ylamine;

as a single tautomer, a mixture of tautomers, a single stereoisomer, a mixture of stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt or solvate thereof.

78. (New) The compound of claim 23 selected from the group consisting of:

(4-Benzothiazol-2-yl-2*H*-pyrazol-3-yl)-methyl-amine;  
[2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazol-6-yl]-methanol;  
[2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-5-yl]-methanol;  
[2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-6-yl]-methanol;  
2-(1*H*-Pyrazol-4-yl)-benzothiazole;  
2-(1*H*-Pyrazol-4-yl)-benzothiazole-6-sulfonic acid amide;  
2-(3-Amino-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-4,5,6-trifluoro-benzothiazole-7-sulfonic acid amide;

2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazole-6-carboxylic acid methyl ester;

2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-carboxylic acid;

2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-carboxylic acid methyl ester;

2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-benzothiazole-7-carboxylic acid methyl ester;

2-(3-Methyl-1*H*-pyrazol-4-yl)-benzothiazole;

2-(5-Amino-1*H*-pyrazol-4-yl)-benzothiazol-6-ylamine;

2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-4-fluorobenzothiazole-6-sulfonic acid amide;

2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide;

2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-5-ol;

2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-carboxylic acid amide;

2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid amide;

2-(5-Amino-3-pyridin-4-yl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid amide;

4-(4-fluorobenzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;

4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-fluoro-phenyl)-2*H*-pyrazol-3-ylamine;

4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-phenyl-cyclopropyl)-2*H*-pyrazol-3-ylamine;

4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(3-fluoro-phenyl)-2*H*-pyrazol-3-ylamine;

4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(4-fluoro-phenyl)-2*H*-pyrazol-3-ylamine;

4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(5-nitro-furan-2-yl)-2*H*-pyrazol-3-ylamine;

4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-furan-2-yl-2*H*-pyrazol-3-ylamine;

4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-isoxazol-5-yl-2*H*-pyrazol-3-ylamine;

4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;

4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-phenyl-2*H*-pyrazol-3-ylamine;

4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-piperazin-1-yl-2*H*-pyrazol-3-ylamine;

4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-pyridin-4-yl-2*H*-pyrazol-3-ylamine;

4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-thiophen-2-yl-2*H*-pyrazol-3-ylamine;

International Application No.: PCT/CA2003/001078

International Filing Date: July 23, 2003

Application No. 10/521,948

Supplemental Preliminary Amendment

4-(5-Fluoro-6-methyl-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methyl-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(5-Methoxy-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(5-Trifluoromethyl-benzothiazol-2-yl)-1*H*-pyrazol-3-ylamine;  
4-(6-Bromo-5-fluoro-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(6-Bromo-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(6-Chlorobenzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(6-Dimethylaminomethyl-5-fluoro-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(6-Dimethylaminomethyl-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(6-Fluoro-benzothiazol-2-yl)-1*H*-pyrazol-3-ylamine;  
4-(6-Fluoro-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(6-Methoxy-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(6-Methoxy-benzothiazol-2-yl)-5-piperazin-1-yl-2*H*-pyrazol-3-ylamine;  
4-(6-Nitro-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
4-(7-chloro-4-methoxy-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(7-Chloro-5-fluoro-6-methoxy-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-1*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-cyclopropyl-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-ethyl-1*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-furan-2-yl-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-methyl-1*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-phenyl-1*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-piperazin-1-yl-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-piperidin-4-yl-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-pyridin-3-yl-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-pyridin-4-yl-2*H*-pyrazol-3-ylamine;

4-Benzothiazol-2-yl-5-pyrrolidin-1-yl-1*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-thiophen-2-yl-2*H*-pyrazol-3-ylamine;  
5-(2-Chloro-pyridin-3-yl)-4-(5-fluoro-6-methoxy-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
5-Cyclopropyl-4-(5-fluoro-6-methoxy-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
5-Methyl-4-(4,5,6-trifluoro-benzothiazol-2-yl)-1*H*-pyrazol-3-ylamine;  
5-Methyl-4-(5-trifluoromethylbenzothiazol-2-yl)-1*H*-pyrazol-3-ylamine;  
5-Methyl-4-(6-methylaminomethyl-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
N-[2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-6-yl]-acetamide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)benzothiazole-5-carboxylic acid ethyl ester;  
2-(3-Phenyl-1*H*-pyrazol-4-yl)benzothiazole; and  
4-Benzothiazol-2-yl-2-methyl-2*H*-pyrazol-3-ylamine.

79. (New) The compound of claim 24 selected from the group consisting of:

[2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazol-6-yl]-methanol;  
[2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-5-yl]-methanol;  
[2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-6-yl]-methanol;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-4,5,6-trifluoro-benzothiazole-7-sulfonic acid amide;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazole-6-carboxylic acid methyl ester;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-carboxylic acid;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-carboxylic acid methyl ester;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-benzothiazole-7-carboxylic acid methyl ester;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-4-fluorobenzothiazole-6-sulfonic acid amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide;

2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-5-ol;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-carboxylic acid amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid amide;  
4-(4-fluorobenzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-phenyl-cyclopropyl)-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-phenyl-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methyl-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(5-Methoxy-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(6-Bromo-5-fluoro-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(6-Bromo-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(6-Chlorobenzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(6-Dimethylaminomethyl-5-fluoro-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(6-Dimethylaminomethyl-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(6-Fluoro-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(6-Methoxy-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(7-chloro-4-methoxy-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(7-Chloro-5-fluoro-6-methoxy-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-cyclopropyl-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-ethyl-1*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-methyl-1*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-methylsulfanyl-1*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-phenyl-1*H*-pyrazol-3-ylamine;  
5-Cyclopropyl-4-(5-fluoro-6-methoxy-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
5-Methyl-4-(4,5,6-trifluoro-benzothiazol-2-yl)-1*H*-pyrazol-3-ylamine;

5-Methyl-4-(5-trifluoromethylbenzothiazol-2-yl)-1*H*-pyrazol-3-ylamine;  
5-Methyl-4-(6-methylaminomethyl-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
N-[2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-6-yl]-acetamide; and  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)benzothiazole-5-carboxylic acid ethyl ester.

80. (New) The compound of claim 27 selected from the group consisting of:

[2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazol-6-yl]-methanol;  
[2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-5-yl]-methanol;  
[2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-6-yl]-methanol;  
2-(1*H*-Pyrazol-4-yl)-benzothiazole-6-sulfonic acid amide;  
2-(3-Amino-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-4,5,6-trifluoro-benzothiazole-7-sulfonic acid  
amide;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazole-6-carboxylic acid methyl  
ester;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-carboxylic acid;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-carboxylic acid methyl ester;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-benzothiazole-7-carboxylic acid methyl ester;  
2-(5-Amino-1*H*-pyrazol-4-yl)-benzothiazol-6-ylamine;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-4-fluorobenzothiazole-6-sulfonic acid amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-5-ol;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-carboxylic acid amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid amide;  
2-(5-Amino-3-pyridin-4-yl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid amide;  
4-(4-fluorobenzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;



4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-fluoro-phenyl)-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-phenyl-cyclopropyl)-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(3-fluoro-phenyl)-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(3-nitro-phenyl)-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(4-fluoro-phenyl)-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(4-methoxy-phenyl)-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-phenyl-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-piperazin-1-yl-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-pyridin-4-yl-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methyl-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-6-methyl-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(5-Fluoro-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(5-Methoxy-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(5-Trifluoromethyl-benzothiazol-2-yl)-1*H*-pyrazol-3-ylamine;  
4-(6-Bromo-5-fluoro-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(6-Bromo-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(6-Chlorobenzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(6-Dimethylaminomethyl-5-fluoro-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(6-Dimethylaminomethyl-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
4-(6-Fluoro-benzothiazol-2-yl)-1*H*-pyrazol-3-ylamine;  
4-(6-Fluoro-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(6-Methoxy-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
4-(6-Methoxy-benzothiazol-2-yl)-5-piperazin-1-yl-2*H*-pyrazol-3-ylamine;  
4-(6-Nitro-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
4-(7-chloro-4-methoxy-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;

4-(7-Chloro-5-fluoro-6-methoxy-benzothiazol-2-yl)-5-methyl-1*H*-pyrazol-3-ylamine;  
5-(2-Chloro-pyridin-3-yl)-4-(5-fluoro-6-methoxy-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
5-Cyclopropyl-4-(5-fluoro-6-methoxy-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
5-Methyl-4-(4,5,6-trifluoro-benzothiazol-2-yl)-1*H*-pyrazol-3-ylamine;  
5-Methyl-4-(5-trifluoromethylbenzothiazol-2-yl)-1*H*-pyrazol-3-ylamine;  
5-Methyl-4-(6-methylaminomethyl-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
N-[2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-6-yl]-acetamide;  
N-{2-[5-Amino-4-(5-fluoro-6-methoxy-benzothiazol-2-yl)-1*H*-pyrazol-3-ylamino]-ethyl}-acetamide;  
*N*<sup>3</sup>-(2-Dimethylamino-ethyl)-4-(5-fluoro-6-methoxy-benzothiazol-2-yl)-1*H*-pyrazole-3,5-diamine;  
*N*<sup>3</sup>-(3-Dimethylamino-propyl)-4-(5-fluoro-6-methoxy-benzothiazol-2-yl)-1*H*-pyrazole-3,5-diamine;  
*N*<sup>3</sup>-[2-(3*H*-Imidazol-4-yl)-ethyl]-4-(6-methoxy-benzothiazol-2-yl)-1*H*-pyrazole-3,5-diamine; or  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)benzothiazole-5-carboxylic acid ethyl ester.

81. (New) The compound of claim 29 selected from the group consisting of:

2-(5-Amino-4-benzothiazol-2-yl-1*H*-pyrazol-3-ylamino)-ethanol;  
2-(5-Amino-4-benzothiazol-2-yl-2*H*-pyrazol-3-ylamino)-cyclopentanol;  
3-(5-Amino-4-benzothiazol-2-yl-1*H*-pyrazol-3-ylamino)-propan-1-ol;  
3-[5-Amino-4-(5-fluoro-6-methoxy-benzothiazol-2-yl)-1*H*-pyrazol-3-ylamino]-propan-1-ol;  
4-(5-Amino-4-benzothiazol-2-yl-1*H*-pyrazol-3-ylamino)-butan-1-ol;  
4-(5-Amino-4-benzothiazol-2-yl-1*H*-pyrazol-3-ylamino)-butyric acid;

4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-*N*<sup>3</sup>-[2-(3*H*-imidazol-4-yl)-ethyl]-1*H*-pyrazole-3,5-diamine;  
4-[(5-Amino-4-benzothiazol-2-yl-1*H*-pyrazol-3-ylamino)-methyl]-benzenesulfonamide;  
4-[2-(5-Amino-4-benzothiazol-2-yl-1*H*-pyrazol-3-ylamino)-ethyl]-phenol;  
4-Benzothiazol-2-yl-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-(1*H*-imidazol-2-ylmethyl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-(1*H*-imidazol-2-ylmethylene)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-(2-dimethylamino-ethyl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-(2-ethylamino-ethyl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-(2-methoxy-ethyl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-(2-pyrrolidin-1-yl-ethyl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-(3-dimethylamino-propyl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-(3-imidazol-1-yl-propyl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-[2-(1*H*-indol-3-yl)-ethyl]-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-piperidin-4-ylmethyl-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>5</sup>-(2-morpholin-4-yl-ethyl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>5</sup>-ethyl-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>5</sup>-pyridin-3-ylmethyl-1*H*-pyrazole-3,5-diamine;  
*N*-[2-(5-Amino-4-benzothiazol-2-yl-1*H*-pyrazol-3-ylamino)-ethyl]-acetamide;  
*N*-{2-[5-Amino-4-(5-fluoro-6-methoxy-benzothiazol-2-yl)-1*H*-pyrazol-3-ylamino]-ethyl}-acetamide;  
*N*<sup>3</sup>-(2-Amino-ethyl)-4-benzothiazol-2-yl-1*H*-pyrazole-3,5-diamine;  
*N*<sup>3</sup>-(2-Dimethylamino-ethyl)-4-(5-fluoro-6-methoxy-benzothiazol-2-yl)-1*H*-pyrazole-3,5-diamine;  
*N*<sup>3</sup>-(3-Dimethylamino-propyl)-4-(5-fluoro-6-methoxy-benzothiazol-2-yl)-1*H*-pyrazole-3,5-diamine;  
*N*<sup>3</sup>-(4-Amino-phenyl)-4-benzothiazol-2-yl-1*H*-pyrazole-3,5-diamine;

*N*<sup>3</sup>-[2-(3*H*-Imidazol-4-yl)-ethyl]-4-(6-methoxy-benzothiazol-2-yl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>5</sup>-benzyl-1*H*-pyrazole-3,5-diamine; ;  
4-Benzothiazol-2-yl-*N*<sup>5</sup>-(3,5-dichlorophenyl)-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>5</sup>-quinolin-6-yl-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-quinolin-5-yl-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>5</sup>-pyridin-3-yl-1*H*-pyrazole-3,5-diamine;  
4-Benzothiazol-2-yl-*N*<sup>5</sup>-pyridin-4-ylmethyl-1*H*-pyrazole-3,5-diamine; and  
4-Benzothiazol-2-yl-*N*<sup>3</sup>-(3-methylbutyl)-1*H*-pyrazole-3,5-diamine.

82. (New) A compound selected from the group consisting of:  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid  
methanamide;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid methanamide;  
2-(3-Amino-5-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (2,6-dimethyl-  
pyrimidin-4-yl)-amide;  
2-(5-Amino-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid methanamide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazole-4-sulfonic acid (2-  
hydroxy-ethyl)-amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid (2-  
hydroxy-ethyl)-amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid (pyridin-  
4-ylmethyl)-amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-5-sulfonic acid methanamide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (2-hydroxy-ethyl)-  
amide;


- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (2-methoxy-ethyl)-amide;
- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid 4-fluoro-benzylamide;
- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (2-thiophen-2-yl-ethyl)-amide;
- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid 4-chloro-benzylamide;
- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid 4-methoxy-benzylamide;
- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid benzylamide;
- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid phenethyl-amide;
- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid [2-(4-amino-phenyl)-ethyl]-amide;
- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (2-morpholin-4-yl-ethyl)-amide;
- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (2,2,2-trifluoro-ethyl)-amide;
- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid cyclopropylmethyl-amide;
- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid [2-(3*H*-imidazol-4-yl)-ethyl]-amide;
- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid 4-amino-benzylamide;
- 2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (pyridin-4-ylmethyl)-amide;

2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (2-dimethylamino-ethyl)-amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (3-dimethylamino-propyl)-amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (acetic hydrazido) amide;  
2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonic acid (phenylhydrazino) amide;  
2- {[2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-6-ylmethyl]-amino}-ethanol;  
3- {[2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazol-6-ylmethyl]-amino}-benzenesulfonamide;  
4-(6-Methanesulfonyl-benzothiazol-2-yl)-5-methyl-2*H*-pyrazol-3-ylamine;  
5-Methyl-4-(6-morpholin-4-ylmethyl-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
5-Methyl-4-(6-pyrrolidin-1-ylmethyl-benzothiazol-2-yl)-2*H*-pyrazol-3-ylamine;  
5-Methyl-4-[6-(4-methyl-piperazin-1-ylmethyl)-benzothiazol-2-yl]-2*H*-pyrazol-3-ylamine;  
5-Methyl-4-[6-(4-methyl-piperazine-1-sulfonyl)-benzothiazol-2-yl]-2*H*-pyrazol-3-ylamine;  
N-{2-[2-(5-Amino-3-methyl-1*H*-pyrazol-4-yl)-benzothiazole-6-sulfonylamino]-ethyl}-acetamide;  
(4-Benzothiazol-2-yl-1*H*-pyrazol-3-yl)-[2-(1*H*-imidazol-4-yl)-ethyl]-amine;  
2-(4-Benzothiazol-2-yl-1*H*-pyrazol-3-yl)-phenol;  
3-(5-Amino-4-benzothiazol-2-yl-1*H*-pyrazol-3-yl)-propan-1-ol;  
4-(4-Benzothiazol-2-yl-1*H*-pyrazol-3-yl)-6-ethyl-benzene-1,3-diol;  
4-(4-Benzothiazol-2-yl-1*H*-pyrazol-3-yl)-benzene-1,3-diol;  
4-(4-Benzothiazol-2-yl-1*H*-pyrazol-3-yl)-phenol;  
4-(5-Amino-4-benzothiazol-2-yl-1*H*-pyrazol-3-yl)-butan-1-ol;

4-(5-Amino-4-benzothiazol-2-yl-2*H*-pyrazol-3-ylamino)-*N*-thiazol-2-yl-benzenesulfonamide;  
4-Benzothiazol-2-yl-5-(3-dimethylamino-propyl)-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-(3-methylamino-propyl)-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-(4-dimethylamino-butyl)-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-(4-methylamino-butyl)-2*H*-pyrazol-3-ylamine;  
4-Benzothiazol-2-yl-5-(4-nitro-phenyl)-2*H*-pyrazol-3-ylamine;  
5-(3-Amino-propyl)-4-benzothiazol-2-yl-2*H*-pyrazol-3-ylamine;  
5-(4-Amino-phenyl)-4-benzothiazol-2-yl-2*H*-pyrazol-3-ylamine;  
*N*-[4-(5-Amino-4-benzothiazol-2-yl-1*H*-pyrazol-3-yl)-phenyl]-hydroxylamine;  
2-[3-(4-Methoxyphenyl)-1*H*-pyrazol-4-yl]benzothiazole; and  
2-[3-(2-Methoxyphenyl)-1*H*-pyrazol-4-yl]benzothiazole;

as a single tautomer, a mixture of tautomers, a single stereoisomer, a mixture of stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt or solvate thereof.

83. (New) A compound of formula (3):



as a single tautomer, a mixture of tautomers, a single stereoisomer, a mixture of stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt or solvate thereof; wherein:

$R^2$  and  $R^3$  at each occurrence is independently selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl,

hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol, thioureido, and ureido;


$R^4$  is selected from hydrogen, heteroalkyl, heteroaryl, and hydrocarbyl;

X is selected from S, O and  $NR^9$ , and  $R^9$  is selected from hydrogen, heteroalkyl, heteroaryl, and hydrocarbyl;

Y is a 6 membered heterocycle having 1 or 2 nitrogen atoms and which is optionally further substituted by one or more groups selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol, thioureido, and ureido.

84. (New) The compound of Claim 83 wherein the compound is 5-Methyl-4-thiazolo[5,4-b]pyridin-2-yl-1H-pyrazol-3-ylamine.

85. (New) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (3):



as a single tautomer, a mixture of tautomers, a single stereoisomer, a mixture of stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt or solvate thereof; wherein:



$R^2$  and  $R^3$  at each occurrence is independently selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol, thioureido, and ureido;

$R^4$  is selected from hydrogen, heteroalkyl, heteroaryl, and hydrocarbyl;

X is selected from S, O and  $NR^9$ , and  $R^9$  is selected from hydrogen, heteroalkyl, heteroaryl, and hydrocarbyl;

Y is a 6 membered heterocycle having 1 or 2 nitrogen atoms and which is optionally further substituted by one or more groups selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol, thioureido, and ureido.

86. (New) A method of treating a hyperproliferative disorder, the method comprising: contacting a patient suffering from said hyperproliferative disorder with an effective dose of a composition according to Claim 85 or of a compound according to Claim 83.

87. (New) A method of inhibiting cell migration or invasion, the method comprising: contacting a patient suffering from a disorder resulting from said cell migration or invasion with an effective dose of a composition according to Claim 85 or of a compound according to Claim 83.

88. (New) A method of inhibiting inflammation, the method comprising: contacting a patient suffering from said inflammation with an effective dose of a composition according to Claim 85 or of a compound according to Claim 83.

International Application No.: PCT/CA2003/001078  
International Filing Date: July 23, 2003  
Application No. 10/521,948  
Supplemental Preliminary Amendment

89. (New) A method of treating renal disease, the method comprising: contacting a patient suffering from said renal disease with an effective dose of a composition according to Claim 85 or of a compound according to Claim 83.